Recs

0

FDA Permits Using Johnson & Johnson Cancer Drug Without Chemo

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

On Monday, Johnson & Johnson (NYSE: JNJ  ) subsidiary Janssen Research & Development confirmed  that the FDA has approved its oral, once-daily medication Zytiga for treatment of metastatic castration-resistant prostate cancer (mCRPC). Before this approval of more expansive usage, Zytiga had been approved for use only on patients who hadn't responded to prior chemotherapy containing docetaxel. As a result, the new "indication" permits doctors to prescribe Zytiga without first recommending chemo.

Additionally, Janssen noted that it has received a "positive opinion" for expanded usage of the drug from the European Medicines Agency's Committee for Medicinal Products for Human Use. Further approvals in other countries are also being sought.

"Excluding skin cancer, prostate cancer is the most frequently diagnosed cancer in men in the U.S.," Janssen noted in a press release. "In 2012, the American Cancer Society estimates more than 28,000 men will die from the disease, making it the second leading cause of cancer death behind lung cancer. There are approximately 35,000 new cases of mCRPC each year."

Shares of Johnson & Johnson closed up 0.2% on the news.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2147358, ~/Articles/ArticleHandler.aspx, 8/2/2015 2:38:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Rich Smith
TMFDitty

As a defense writer for The Motley Fool, I focus on defense and aerospace stocks. My job? Every day of the week, I'm monitoring the news, figuring out the winners and losers, and tracking down the promising companies for you to invest in. Follow me on Twitter or Facebook for the most important developments in defense & aerospace, and other great stories.

Today's Market

updated 1 day ago Sponsored by:
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASD 5,128.28 -0.50 -0.01%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

7/31/2015 4:00 PM
JNJ $100.21 Up +0.37 +0.37%
Johnson & Johnson CAPS Rating: ****

Advertisement